Side effects of Ozempic semaglutide injection: a plain guide

What side effects does semaglutide injection typically cause?

The side effects most people encounter with semaglutide injection are centred on the digestive system. Nausea tops the list; vomiting, diarrhoea, constipation, burping, and acid reflux follow. Fatigue, mild headache, and dizziness appear less often. Injection-site reactions (a little redness or itching where the pen was used) are also reported, though rarely troublesome. The NHS semaglutide medicines page sets these out clearly and is a good first reference alongside your patient information leaflet.

Timing matters here. Most GI effects peak when treatment begins or when a dose steps up, then fade as the body adapts — often within days to a fortnight. Eating smaller portions, staying well hydrated, and avoiding very fatty meals tends to help. These are practical steps rather than clinical instructions; your prescriber and the patient information leaflet are the right places for personal guidance.

A question our prescribers hear most weeks is whether the nausea ever goes away entirely. For most people it does, though a small proportion find it persists at higher doses. That is one reason the titration schedule exists, giving the body time to settle at each level before moving up.

The side-effect profile of Ozempic and Wegovy is broadly similar, since both contain semaglutide; differences mainly relate to dose. For a broader look across the injectable weight-loss medicine class, this overview of weight-loss injection side effects covers the wider picture.

When should you get medical help?

Most side effects from semaglutide are mild and self-limiting. A few, however, warrant urgent attention.

Severe, persistent stomach pain (especially pain that spreads toward the back, with or without vomiting) should prompt a same-day call to your GP or a visit to urgent care. This pattern can indicate acute pancreatitis, a known but uncommon risk with GLP-1 medicines. In January 2026, the MHRA issued a formal Drug Safety Update highlighting pancreatitis across the GLP-1 class; you can review it through the MHRA Drug Safety Update index.

Gallbladder problems (right-sided upper abdominal pain, sometimes with fever or jaundice) also warrant prompt assessment. Significant dehydration from repeated vomiting or diarrhoea can strain the kidneys; if you cannot keep fluids down for more than a day, seek help rather than waiting it out.

Signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing, rapid heartbeat) need emergency care immediately. People with type 2 diabetes taking semaglutide alongside certain other medicines should also be alert to low blood sugar symptoms: shakiness, sweating, confusion.

If you notice low mood, unusual thoughts, or changes in mental wellbeing, speak to your prescriber. The link between GLP-1 medicines and mood is an active area of monitoring. None of these warnings are reasons to avoid treatment, but they are reasons to stay informed and to have a prescriber you can actually reach.

Does Ozempic cause the same side effects as Wegovy, given they are both semaglutide?

Yes and no. The underlying molecule is identical, which is why the side-effect categories overlap almost completely. The difference is dose: Ozempic for diabetes tops out at 2mg weekly; Wegovy for weight management reaches 2.4mg (and up to 7.2mg with the higher-dose pen approved in April 2026). Higher doses generally bring a somewhat higher frequency of GI side effects, particularly nausea at the start of each new level.

The licences are distinct too. Ozempic is authorised by the MHRA for type 2 diabetes. Wegovy is authorised for weight management in adults with a BMI of 30 or above, or 27-plus with a weight-related health condition. Prescribing one for the other's indication is off-label and carries different clinical considerations. This page explains the relationship between semaglutide, Ozempic and Wegovy in more detail.

If you are researching semaglutide because you are thinking about weight management, the right starting point is the licensed product at the right dose, assessed by a qualified prescriber who knows your full health picture.

Ozempic is for diabetes, what is licensed for weight loss in the UK?

This is worth stating plainly, because the confusion is widespread. Ozempic (semaglutide) is licensed in the UK for type 2 diabetes. It is not licensed for weight loss, and the MHRA is clear that GLP-1 medicines should not be used for cosmetic or quick weight reduction.

The two medicines licensed specifically for weight management in the UK are Wegovy (semaglutide at 2.4mg or 7.2mg) and Mounjaro (tirzepatide, a dual GIP and GLP-1 receptor agonist). Both are prescription-only medicines requiring a full clinical assessment before a prescription can be issued.

If you are exploring Wegovy, our Wegovy page covers what is known about the treatment, its evidence base and the eligibility criteria. For a broader look at what private weight-loss treatment involves, the weight-loss treatments overview is a useful starting point. Pricing context for Wegovy (because it comes up) is covered on the Wegovy cost page.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber who can talk through which medicine, if any, suits your specific circumstances. Side effects and suitability are part of that conversation. If you want to explore whether treatment is right for you, speak to our prescribers through a free consultation.